[Shared Decision-Making in Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder].

Abstract

In multiple sclerosis and neuromyelitis optica spectrum disorders, several new, highly effective drugs have been developed in recent years, and the prognosis for patients has improved. However, treatment has become more complex, and healthcare professionals should explain the efficacy and safety of drugs to patients and engage in shared decision-making (SDM) that considers the patient's preferences and values. Further studies are required to determine whether SDM is associated with patient outcomes.